Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

l controlled period (27 percent) and the incidence decreased to 16 percent from week 30 to week 156. No major hypoglycemia was observed.

DURATION-3 (277-OR)
Oral Presentation – Monday, June 27, 9-9:15 a.m.
Of the patients enrolled in the DURATION-3 study, 390 entered the open-label, comparator-controlled extension study after 26 weeks of treatment with either BYDUREON or Lantus, and 173 patients in each treatment group completed the 84-week extension. A similar proportion of patients in each treatment group achieved the study endpoint of A1C less than 7 percent (BYDUREON: 45 percent; Lantus: 37 percent; p=0.084). However, a higher proportion of patients on BYDUREON achieved A1C less than or equal to 6.5 percent compared to those on Lantus (BYDUREON: 31 percent; Lantus: 20 percent; p=0.009).

BYDUREON was well tolerated during the treatment period. The most common adverse event was nasopharyngitis in both treatment arms, as well as nausea in the BYDUREON group and headache in the Lantus group. Patients taking BYDUREON reported significantly fewer episodes of confirmed hypoglycemia.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(i,ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs more than $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... (MGH) researchers have identified a new molecular pathway that ... This early-stage kidney disease affects 100 million people around ... the kidneys filtering structures. Blocking this pathway could ... slow the process of kidney failure. The research ...
... impact on behavior, studies show , , WEDNESDAY, Dec. 19 (HealthDay ... trillion cells, looking for perhaps only one or a handful ... of new studies says. , The research, conducted with rodents ... , could rewrite the textbooks on just how important individual ...
... a way to use a firefly gene to let them ... against some forms of cancer and its serious complication. ... and leukemia, a form of cancer where it is particularly ... prognosis is generally poor. There is now no widely effective ...
... Helping Latino Nonprofits and Families With Cash,Donation. Photo ... Latino with,HIV., WASHINGTON, Dec. 19 The ... This holiday season, MAYA is giving $10,000 to ... the Latino community.,MAYA will also donate cash to ...
... Health Net of California See Big Increases in ... Surveyor from HealthLeaders-InterStudy Reveals ... NASHVILLE, Tenn., Dec. 19 HealthLeaders-InterStudy, the,leading ... managed,care enrollment from January 2007 to July 2007 ...
... volunteer John,Cleland has run four marathons, but the race ... Diagnosed with the disease as a college,undergraduate, Cleland underwent ... punishing rounds of chemotherapy followed. But when,Cleland,s cancer spread ... Then Cleland,s doctor offered one small ray of ...
Cached Medicine News:Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3Health News:HIV/AIDS Rate Increases in DC Area Latino Population, Community Lacks Resources 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 3Health News:New Book Looks at Clinical Research from the Patient's Point of View 2Health News:New Book Looks at Clinical Research from the Patient's Point of View 3
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: